key: cord-0731276-jkq4cszb
authors: Eguiluz‐Gracia, Ibon; van den Berge, Maarten; Boccabella, Cristina; Bonini, Matteo; Caruso, Cristiano; Couto, Mariana; Erkekol, FerdaOner; Rukhadze, Maia; Sanchez‐Garcia, Silvia; del Giacco, Stefano; Jutel, Marek; Agache, Ioana
title: Real‐life impact of COVID‐19 pandemic lockdown on the management of pediatric and adult asthma: A survey by the EAACI Asthma Section
date: 2021-04-07
journal: Allergy
DOI: 10.1111/all.14831
sha: e80e2737ec0cc806c488eecfc0826aaa75cbad3b
doc_id: 731276
cord_uid: jkq4cszb

BACKGROUND: The restrictions imposed by the COVID‐19 pandemic impact heavily the management of chronic diseases like asthma. This study aimed to evaluate the management of adults and children with asthma during COVID‐19‐related lockdown. METHODS: A survey was launched by the European Academy of Allergy and Clinical Immunology (EAACI) via e‐mail, website, and social media to EAACI members and members of peer societies. RESULTS: The survey was completed by 339 healthcare professionals from 52 countries. 79% of follow‐up consultations were replaced by phone calls, whereas 49% of newly referred patients attended the clinic. 62%, 76%, 66%, 76%, and 87% of responders did not conduct spirometry, impulse oscillometry, bronchodilator test, FeNO, or methacholine provocation, respectively, for asthma diagnosis in adults. The numbers were similar for children. 73% of responders based the initial asthma diagnosis and the prescription of inhaled therapy on clinical parameters only. Lung function tests were used in 29% of cases to monitor asthma worsening, and only 56% of participants were recommended to their patients ambulatory peak expiratory flow (PEF) measurements. Using a 1 (not at all) to 5 (very much) scale, the responders considered that the quality of healthcare provided and the patients’ asthma status had deteriorated during the lockdown with 3.2 points and 2.8 points, respectively. CONCLUSION: Collectively, these results suggest that all necessary resources should be allocated to ensure the performance of lung function tests for initial diagnosis, whereas digital remote monitoring should be reinforced for the follow‐up of children and adults with asthma.

The COVID-19 pandemic challenges the capacity of healthcare systems to provide adequate management of chronic diseases. [1] [2] [3] Among other factors, discontinuation of face-to-face visits and the inability to perform diagnostic tests have a great impact on disease severity and degree of control. 4 A recent survey conducted by the Pediatric Asthma in Real Life (PEARL) think tank showed that the COVID-19 pandemic significantly impacts pediatric asthma services: 39%, 47%, and 75% of them ceased physical appointments, stopped accepting new patients, and limited patients' visits, respectively. Importantly, consultations were almost halved to a median of 20 patients per week, and virtual clinics and helplines were launched in most centers. 5 Another recent survey conducted among Chinese adult asthmatics reported that 75% of them did not attend any follow-up consultation since the beginning the pandemic. 6 Both the initial diagnosis and subsequent monitoring of asthma largely rely on lung function tests (LFTs), which have a welldocumented value and are required by all international guidelines. 7 were similar for children. 73% of responders based the initial asthma diagnosis and the prescription of inhaled therapy on clinical parameters only. Lung function tests were used in 29% of cases to monitor asthma worsening, and only 56% of participants were recommended to their patients ambulatory peak expiratory flow (PEF) measurements. Using a 1 (not at all) to 5 (very much) scale, the responders considered that the quality of healthcare provided and the patients' asthma status had deteriorated during the lockdown with 3.2 points and 2.8 points, respectively.

Collectively, these results suggest that all necessary resources should be allocated to ensure the performance of lung function tests for initial diagnosis, whereas digital remote monitoring should be reinforced for the follow-up of children and adults with asthma.

asthma, COVID-19 lockdown, exacerbations, lung function test, peak expiratory flow G R A P H I C A L A B S T R A C T During the first wave of COVID-19 pandemic, 38% of new and 77% of follow-up consultations for pediatric and adult asthma patients were performed by phone calls. In 10% of cases, both types of consultations continued as face-to-face visits, whereas in 6% of cases all consultations were cancelled. Forced spirometry was not conducted during the initial assessment and subsequent monitoring of 56%-62% of pediatric and adult asthma patients. Only 56% of HCP encouraged asthma patients to perform regular ambulatory peak expiratory flow measurement. Lung function tests were conducted in only 29% of children and adults with asthma who reported a worsening of their clinical condition. Using a 1 (nothing) to 5 (very much) scale, HCP scored with 2.8 the deleterious impact of COVID-19 lockdown on the health status of children and adults with asthma.

Forced spirometry (FS), among other LFTs, has raised safety concerns, especially due to the potential generation of SARS-CoV-2carrying bioaerosols. 8 Of note, the act of forced exhalation generates oral fluid droplets of variable size that can harbor infectious particles. While large droplets fall quickly to the ground, small droplets can dehydrate and linger as bioaerosols in the air, thus functioning as vectors for viral transmission. 9 A recent study revealed that the mere pronunciation of the words "stay healthy" generates 227-347 droplets depending on the lung volume of the speaker. 10 To evaluate the impact of the lockdown restrictions related to COVID-19 pandemic on the management and health status of children and adults with asthma, the Asthma Section of the European Academy of Allergy and Clinical Immunology (EAACI) conducted a survey among EAACI members and members of other international scientific societies in July 2020. Of note, all countries around the world had been affected by the first wave of the pandemic at that moment. 11

The survey was generated by the authors. The specific topics on asthma management evaluated are listed in Appendix S1 in the online supplementary material. 

Because EAACI membership includes professionals who do not take care of asthma patients (basic scientists, dermatologists, ENT surgeons, dieticians, etc.), only clinicians and allied health professionals (eg nurses) totally or partially committed to adult and/or pediatric asthma were asked to reply to the survey. Moreover, the responders were instructed to refer to the hardest moment of the lockdown.

Overall, 339 individuals from Europe (76%), America (18%), Asia (4%), Africa (2%), and Australia (0.3%) (52 different countries, see Appendix S1) participated in the survey, of whom 74% replied to all questions. The most frequent profile of the responder was an allergy specialist (60%), working in a University Hospital (36%) and taking care of both children and adults (41%) (Figure 1 ).

The survey first interrogated the participants for the availability of national guidelines on asthma management during COVID-19 pandemic. These documents existed in most countries (37 of 52), and 74% of responders followed their recommendations. Nevertheless, 39% of participants were already following a similar approach before being aware of the guidelines.

During the lockdown, follow-up consultations were replaced by phone calls in 77% of cases, whereas only 49% of newly referred patients could attend the clinic in person. Of note, only in 10% of cases face-to-face visits were not somehow restricted ( Figure 2 ).

Regarding the performance of LFTs, 62%, 78%, 66%, 76%, and 87% of responders who had the test available at their department did not conduct FS, impulse oscillometry (IOS), bronchodilator test (BDT), fractional exhaled nitric oxide (FeNO) measurement or airway hyperresponsiveness (AHR) tests (eg methacholine bronchial provocation), respectively, for asthma diagnosis in adults ( Figure 3A ).

Similarly, 56%, 62%, 61%, and 70% of participants with access to the tests did not use FS, IOS, BDT, and AHR test for the diagnosis of pediatric asthma. The numbers were similar for the monitoring using LFT both for children and adults with asthma ( Figure 3B ). Importantly, 65% of participants did not conduct any LFT during the lockdown, and only in 15% of cases, more than one test per day and per device was performed.

In a third step, the survey analyzed how asthma was managed during the pandemic. In 73% of cases, the physicians diagnosed asthma and prescribed inhaled therapy based on suggestive symptoms only ( Figure 4A ). Only 19% of participants conducted a full diagnostic workup for asthma diagnosis. Regarding patient monitoring, 69%-72% of responders used only the current symptoms and the asthma history to adjust the treatment. LFTs were used in only 29% of cases to monitor patients reporting a clinical worsening ( Figure 4B ).

The survey particularly focused on the ambulatory measurement of peak expiratory flow (PEF), as this test can be performed using portable devices and can assist in monitoring asthma control, together with asthma symptoms, as part of a management plan. 7 

When the survey was launched, restrictions associated with the first wave of the pandemic were loosening in many countries. 11 Therefore, the next step of the questionnaire evaluated the timeline to resume LFTs and the optimal strategy for future months. As per July 2020, only a minority of centers had reinitiated LFTs (17%-48% depending on the LFT type). Of note, in 53% of cases there was no specific timeline to resume AHR tests ( Figure 5A ). As for the remaining period of the pandemic, 63% of responders stated that LFTs should be restricted to selected patients and only performed after the healthcare facilities have been adapted to the new safety requirements.

Importantly, only 17% of participants believed that the number of LFTs should remain similar to that prior to the lockdown ( Figure 5B ). 

In a last step of the survey, participants were asked to appreciate the deleterious impact of the pandemic on the management and evolution of asthma patients. Using a 1 (not at all) to 5 (very much) scale, the responders considered that both the quality of asthma-related health care provided and the patients' asthma status had deteriorated during lockdown with 3.2 points and 2.8 points, respectively ( Figure 6 ). Although 15%-17% of participants considered that the quality of health care had decreased very much (5 of 5 

This EAACI position paper reports on a real-life situation experienced by physicians managing asthma patients during the first lockdown of the COVID-19 pandemic. Although a larger sample size would have been desirable, the number of survey participants is in line with previous multinational studies using a similar methodology. 5, 12 Even though national guidelines for asthma management during the pandemic existed in most countries, in many cases they

were not crucial to determine the strategy to follow, as the responders were following the same approach before being aware of the guidelines. As previously reported, 13 this observation probably reflects that most national documents were mainly based on expertconsensus just providing common sense recommendations that would be anyways implemented.

The survey reported that most patients referred for initial evaluation underwent phone consultations instead of face-to-face visits.

Therefore, LFTs could not be not performed and asthma diagnosis was guided only by clinical parameters. As previously demonstrated, this approach is associated with a significant rate of misdiagnosis and overtreatment with inhaled corticosteroids (ICS). 14,15 Importantly, ICS therapy is not indicated in all patients with COPD, a disease within the differential diagnosis of asthma. Of note, ICS therapy has been related to a higher risk of both bacterial pneumonia and bone fractures in COPD individuals. 16, 17 On the other hand, follow-up consultations were also conducted by phone calls in most cases. In this regard, the use of FS and FeNO measurement for the management of pediatric asthma has been associated with reduced exacerbation rates, among other beneficial outcomes. 18, 19 Existing evidence indicates that the ambulatory measurement of PEF, as part of a self-management plan, is useful to monitor the disease and decrease the rate of severe exacerbations in both children and adults with asthma. 20 Although the responders expressed no concern of reduced safety of AIT in real-life circumstances, the survey showed a significant under use of AIT during the pandemic. Although temporary, this phenomenon could be associated with a long-lasting negative impact on the clinical care of patients with airway allergy.

The EAACI survey indicates that beyond SARS-CoV-2 infection, the restrictions related to the lockdown significantly impact the quality of health care provided to asthma patients. Unlike previous studies focusing on specific age ranges or countries, 5, 6 the EAACI survey reflects the impact of COVID-19 on adult and pediatric patients from different geographical areas. On the other hand, part of the data collected in EAACI survey is only indicative of the subjective appreciation of the responders. Moreover, similar to previous multinational surveys on allergy, 5,12 our study has a predominance of European responders, especially from Mediterranean countries. This finding likely reflects both the origin of EAACI membership and the regional differences in the implementation of Allergy specialty. In summary, given the wellestablished reliability of LFTs for asthma management, 7, 13, [18] [19] [20] [21] [22] all necessary resources should be allocated to ensure the performance of LFTs for initial asthma diagnosis, whereas PEF measurement should be reinforced for asthma tele-monitoring, both in children and in adults (Table S1 ). In this regard, several national societies have recently published recommendations for safe lung function testing during the COVID-19 pandemic. 31-3 4 All these actions are necessary steps to guarantee the best possible health status of children and adults with asthma during present and future pandemics.

Management of patients with chronic rhinosinusitis during the COVID-19 pandemic -an EAACI Position Paper

Managing ocular allergy in the time of COVID-19

Handling of allergen immunotherapy in the COVID-19 pandemic: an ARIA-EAACI statement

ARIA-EAACI statement on asthma and COVID-19

Impact of COVID-19 on pediatric asthma: practice adjustments and disease burden

Asthma control, self-management, and healthcare access during the COVID-19 epidemic in Beijing

The Global Initiative for Asthma (GINA) 2020 update

A compendium answering 150 questions on COVID-19 and SARS-CoV-2

Mechanistic insights into the effect of humidity on airborne influenza virus survival, transmission and incidence

Visualizing speechgenerated oral fluid droplets with laser light scattering

World Health Organization. Coronavirus disease (COVID-19) pandemic

The EAACI-AAAAI-WAO Junior Members' joint survey: a worldwide snapshot of Allergy and Clinical Immunology specialty

Practical considerations for spirometry during the COVID-19 outbreak: literature review and insights

Overdiagnosis of asthma in the community

Negative methacholine challenge tests in subjects who report physician-diagnosed asthma

Inhaled corticosteroids in COPD and the risk of serious pneumonia

Inhaled glucocorticoids are associated with vertebral fractures in COPD patients

Change in FEV(1) and feno measurements as predictors of future asthma outcomes in children

Advances and recent developments in asthma in 2020

Using quality-control analysis of peak expiratory flow recordings to guide therapy for asthma

Use of peak flow-based self-management plans by adult asthmatic patients

Increasing ICS treatment within supported self-management for children and young people: Asthma: diagnosis, monitoring and chronic asthma management: Evidence review A. London: National Institute of Health and Care Excellence

Peak expiratory flow meters (PEFMs)-who uses them and how and does education affect the pattern of utilisation?

Compliance with peak expiratory flow monitoring in home management of asthma

American College of Allergy, Asthma & Immunology position paper on the use of telemedicine for allergists

The role of mobile health technologies in allergy care: An EAACI position paper

Promising peak flow diary compliance with an electronic peak flow meter and linked smartphone app

The impact of lockdown on allergic rhinitis: what is good and what is bad?

The need for clean air: the way air pollution and climate change affect allergic rhinitis and asthma

COVID-19 pandemic an allergen immunotherapy-an EAACI survey

Upper and lower airways functional examination in asthma and respiratory allergic deseases. Considerations in the SARS-CoV-2 post-pandemic situation

Spirometry during the SARS-CoV-2 pandemic. Guidelines and practical advice from the expert panel of Respiratory Physiopathology Assembly of Polish Respiratory Society

Italian pediatric respiratory society recommendations on pediatric pulmonary function testing during COVID-19 pandemic

Turkish Thoracic Society Experts Consensus Report: recommendations for pulmonary function tests during and after COVID 19 pandemic

Real-life impact of COVID-19 pandemic lockdown on the management of pediatric and adult asthma: A survey by the EAACI Asthma Section

The authors express their gratitude to Ana Antunes, the rest of the EAACI headquarters staff and EAACI Junior Members for fine-tuning and disseminating the survey, to representatives from the American

Academy of Allergy, Asthma and Immunology (AAAAI), the World Allergy Organization (WAO), and the European Respiratory Society (ERS) for promoting this initiative, and to all physicians and allied health professionals who replied to the survey for sharing their valuable experience.